Fredun Pharmaceuticals Limited has reported a robust financial performance for the first quarter, with significant growth across key metrics. The company also announced the appointment of two new independent directors to its board.

Strong Financial Performance

The Mumbai-based pharmaceutical company saw its net profit soar by 64% year-over-year to ₹6.77 crore in Q1, compared to ₹4.13 crore in the same period last year. This impressive growth was accompanied by a 52% increase in total income, which reached ₹119.86 crore.

Fredun Pharmaceuticals' EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) grew by 62% to ₹16.99 crore, with the EBITDA margin improving to 14.18% from 13.30% in the previous year. The company's diluted earnings per share (EPS) also saw a significant rise of 63% to ₹14.33.

Key Financial Highlights

Business Expansion and Order Book

Fredun Pharmaceuticals, which operates across generics, cosmeceuticals, nutraceuticals, mobility aids, and animal healthcare products, reported having over 1,200 products under registration. The company maintains a strong order book exceeding ₹200 crore, providing solid revenue visibility for upcoming quarters.

During the quarter, the company's subsidiary acquired a controlling stake in One Pet Stop, marking its entry into the organized pet care market. This strategic move is expected to expand Fredun's pet care business.

Credit Rating Upgrade

The company received a credit rating upgrade to IVR BBB/Stable from IVR BBB-/Stable for facilities totaling ₹139.64 crore. This upgrade reflects the company's improving financial profile and business prospects.

Board Appointments

In addition to the financial results, Fredun Pharmaceuticals announced the appointment of two new independent directors to its board:

1. Mr. Anshu Agarwal (DIN: 11206436): A Chartered Accountant and Certified Public Accountant with expertise in financial accounting, analytics, and auditing.

2. Ms. Sonal Desai (DIN: 11167642): A Company Secretary with extensive knowledge in corporate laws, governance, and compliance.

Both appointments are for a term of five years, effective July 30, 2025, subject to shareholder approval.

As Fredun Pharmaceuticals continues to strengthen its market position and diversify its product portfolio, the company appears well-positioned for sustained growth in the dynamic pharmaceutical and healthcare sectors.

Fredun Pharmaceuticals has announced significant developments following its board meeting held on July 30, 2025. The company's Board of Directors approved the unaudited financial results for the quarter ended June 30, 2025, and made two key appointments to strengthen its leadership team.

Board Approves Q1 Financial Results

The pharmaceutical company's board has approved the unaudited financial results for the first quarter of the fiscal year 2025-26. These results, along with the Limited Review Report issued by M/s. R.H. Nisar & Co, the company's Statutory Auditors, have been submitted in compliance with SEBI regulations.

Appointment of New Independent Directors

In a move to enhance its corporate governance, Fredun Pharmaceuticals has appointed two new Additional Directors in the category of Independent Directors:

1. Mr. Anshu Agarwal (DIN: 11206436): Appointed for a five-year term, effective July 30, 2025, subject to shareholder approval. Mr. Agarwal brings a strong financial background to the board:

   • Bachelor's degree in Commerce from Mumbai University (2018)
   • Indian Chartered Accountant (2020)
   • Master's degree in Accounting and Analytics from Rochester Institute of Technology
   • US Certified Public Accountant certified by the American Institute of Certified Public Accountants in Guam (2024)
   • Currently works as an Audit Associate at Fust Charles LLP

2. Ms. Sonal Desai (DIN: 11167642): Also appointed for a five-year term, effective July 30, 2025, subject to shareholder approval. Ms. Desai's expertise includes:

   • Strong academic background in law and commerce
   • Extensive knowledge of corporate laws, governance, and compliance
   • Experience in handling board meetings, secretarial matters, and corporate affairs
   • Worked across various industries including real estate, pharmaceuticals, and aluminum composite panels

Both appointees are not related to the Promoter or Promoter Group and meet the independence criteria under applicable regulations.

Trading Window Closure

The company had previously closed the trading window for insiders from July 1, 2025, until 48 hours after the declaration of the board meeting outcome, in line with regulatory requirements.

Upcoming Earnings Conference Call

Fredun Pharmaceuticals has scheduled an Earnings Conference Call for Friday, August 1, 2025, at 11:00 a.m. to discuss the financial results for the quarter ended June 30, 2025. Interested parties can register for the call using the provided link or dial in directly.

These developments underscore Fredun Pharmaceuticals' commitment to transparency, corporate governance, and shareholder engagement as it moves forward in the pharmaceutical sector.